Clinical trial
A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1 Alpha
NCT00117013 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1 Alpha
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 28, 2005
- Completion date
- October 25, 2010
- Enrollment
- 16 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.